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Disorders of Sex Development
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Department of Urology, University of Ulsan College of Medicine, Seoul, Korea
The birth of a new baby is one of the most dramatic events in a family, and the first 
question is usually “is it a boy or a girl?” The newborn infant with ambiguous external 
genitalia often comes as a surprise for the doctors as well as the parents and is sometimes 
described as an endocrine emergency situation presenting a problem of sex assignment. 
The nomenclature such as ‘intersex’, ‘hermaphrodite’, and ‘pseudohermaphrodite’ is 
out of date as well as confusing, and many urologists are concerned that these confusing 
terms could be perceived to be pejorative by some affected families. In response to con-
cerns regarding outdated and controversial terms, the Chicago Consensus held in 2005 
recommended new terminology based on the umbrella term disorders of sex differ-
entiation (DSDs). The term DSD has a comprehensive definition including any problem 
noted at birth in which the genitalia are atypical in relation to the chromosomes or 
gonads. The karyotype is used as a prefix defining the classification of DSD. DSDs are 
rare and complex. The optimal management of patients with DSD must be in-
dividualized and multidisciplinary, considering all aspects, including psychological 
care and full disclosure of alternatives relating to surgery type and timing. Although 
further studies are necessary to confirm guidelines and recommendations fitting for 
the individual patients with DSD, this article is an attempt to provide a balanced per-
spective for new taxonomy, clinical evaluation, and medical, surgical, and psychological 
management of DSD. 
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INTRODUCTION
The newborn infant with ambiguous external genitalia 
presents a problem of sex assignment and is frequently de-
scribed as a clinical emergent situation that is distressing 
to the parents. The word intersex has conventionally been 
used to refer to the appearance of the external genitalia be-
ing at variance with normal development for either sex; 
however, this term is not favored by many families with am-
biguous genitalia [1]. A multidisciplinary meeting of medi-
cal and nonmedical experts in Chicago in 2005 (the Chicago 
Consensus) established revised nomenclature and treat-
ment recommendations in individuals with the newly de-
fined term disorders of sex differentiation (DSDs) replacing 
terms such as intersex, hermaphroditism, and pseudo-
hermaphroditism [2-4]. DSDs are defined as congenital 
conditions associated with atypical development of chro-
mosomal, gonadal, or anatomical sex [4]. There are limited 
data on the incidence of DSDs; it is estimated that the over-
all incidence of DSDs is one in 5,500 [5,6]. Congenital adre-
nal hyperplasia (CAH) and mixed gonadal dysgenesis are 
the most common causes of ambiguous genitalia, constitut-
ing approximately over 50% of all cases of genital ambi-
guity in the newborn period [7]. The incidence of CAH and 
mixed gonadal dysgenesis worldwide is 1:15,000 and 
1:10,000, respectively, but varies considerably among dif-
ferent populations [8,9]. Confirming a cause for DSD and 
devising a management plan is one of the most challenging 
clinical conditions for the pediatric urologist. It is im-
portant to diagnose DSDs correctly as soon as possible to 
counsel the parents appropriately. The evaluation and 
management of DSDs is complex, and a multidisciplinary 
team approach including a pediatric urologist, a psychia-
trist, and a pediatric endocrinologist is required for optimal Korean J Urol 2012;53:1-8
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TABLE 1. Revised nomenclature
Previous Revised
Intersex
Male pseudohermaphrodite
Undervirilization of an XY male
Undermasculinization of an XY male
Female pseudohermaphrodite
Overvirilization of an XX female
Masculinization of an XX female
True hermaphrodite
XX male or XX sex reversal
XY sex reversal
Disorders of sex 
development (DSDs)
46,XY DSD
46,XX DSD
Ovotesticular DSD
46,XX testicular DSD
46,XY complete gonadal 
dysgenesis
TABLE 2. DSD classification proposed by the Chicago consensus
Sex chromosome DSD 46,XY DSD 46,XX DSD
45,X (Turner syndrome and variants)
47,XXY (Klinefelter syndrome 
andvariants)
45,X/46,XY (mixed gonadaldysgenesis, 
ovotesticular DSD)
46,XX/46,XY (chimeric,ovotesticular 
DSD)
Disorders of gonadal (testicular) 
development
Complete gonadal dysgenesis (Swyer 
syndrome)
Partial gonadal dysgenesis
Gonadal regression
Ovotesticular DSD
Disorders in androgen synthesis or action
Androgen biosynthesis defect 
(17-hydroxysteroid dehydrogenase 
deficiency, 5α-reductasedeficiency)
Defect in androgen action (CAIS, PAIS)
LH receptor defects (Leydig 
cellhypoplasia)
Disorders of AMH and AMH receptor 
(persistent müllerian duct syndrome)
Other (severe hypospadias, 
cloacalextrophy)
Disorders of gonadal (ovarian) development
Ovotesticular DSD
Testicular DSD (SRY+, dup SOX9)
Gonadal dysgenesis
Androgen excess
Fetal (21- or 11-hydroxylase deficiency)
Fetoplacental (aromatase deficiency, 
POR)
Maternal (luteoma, exogenous)
Other (cloacalextrophy, MURCS)
DSD, disorder of sex development; CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; 
LH, luteinizing hormone; AMH, anti-müllerian hormone; POR, cytochrome P450 oxidoreductase; MURCS, müllerian duct aplasia; 
renal aplasia, and cervicothoracic somite dysplasia.
management [4,10-12], with communication with the pri-
mary care physician [13]. This article is an attempt to out-
line pragmatic perspectives in the approach to patients 
with DSDs. 
NOMENCLATURE AND CLASSIFICATION OF DSD
1. Dilemma of the preexisting nomenclature
Advances in understanding the molecular genetic causes 
of abnormal sexual development and heightened aware-
ness of the ethical and patient-advocacy issues mandated 
a reexamination of preexisting nomenclature [11]. Termi-
nologies such as intersex, hermaphroditism, and pseudo-
hermaphroditism are controversial; potentially pejorative 
to patients; and confusing even to urologists [1]. Therefore, 
the term DSD was proposed to indicate congenital con-
ditions with atypical development of chromosomal, gona-
dal, or anatomic sex. A classification is proposed in which 
DSDs associated with sex chromosome abnormalities (sex 
chromosome DSD) were separated from DSDs with a nor-
mal chromosome complement (46,XX DSD and 46,XY 
DSD). The stigmatizing term intersex has thus been re-
placed by a more general and descriptive term, DSD. 
2. New classification based on Chicago consensus
Table 1 summarizes the new taxonomy and Table 2 shows 
the application of the new nomenclatures  in clinical 
situations. Although DSD may be useful as a more global 
term, these general subcategories seem too nonspecific and 
less useful to specific clinical situations. Adding diagnostic 
specificity to the comprehensive DSD definition utilizes 
knowledge of the karyotype, which is based on recognizing 
the central role of karyotype analysis in the investigation 
of DSDs. Subsequently, the confusing mythological term 
pseudohermaphroditism is replaced. The original sum-
mary publications of the Chicago Consensus have not pro-
vided precise classifications of the DSDs; therefore, incon-
sistency exists between the DSD classifications used by 
each investigator. Further clinical classification based on 
a primary genetic defect is preferred when available be-
cause these could more clearly predict disease-specific 
outcomes. Although there are potential criticisms to the 
new nomenclature, the DSD terminology has been gen-
erally accepted and is now popularly used in the literature. 
This term DSD is seen in conferences, in the scientific liter-
ature, and even in text books of endocrinology. For exam-Korean J Urol 2012;53:1-8
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FIG. 1. Medical photographs of pati-
ents suggestive of 46,XX disorders of 
sex differentiation (DSD) (ovotesti-
cular DSD). Asymmetric labioscrotal 
fold and perineal-type hypospadias 
were detected through the physical 
examination. After exploration, the ri-
ght gonad was determined as an ovary 
and the left gonad as ovotestis. 
ple, the International Society for Hypospadias and 
Intersex Disorders titled its World Congress “Hypospadias 
and Disorders of Sex Development.”
CLINICAL EVALUATION OF DSD
The birth of a child with ambiguous external genitalia is 
highly distressing to families. The first question parents 
ask about their newborn is whether it is a boy or a girl. The 
birth of a newborn with ambiguous genitalia comes as a 
surprise for the parents and doctors alike. Although some 
researchers report that 60% of affected children are diag-
nosed prenatally, many parents are faced with the sit-
uation at birth [14]. Healthcare professionals involved in 
the care of a child with DSD should emphasize to families 
that a child with DSD has the potential to become a well-ad-
justed, functional member of society [15]. 
1. History
An initial approach begins with a complete family and pre-
natal history taking [4,12]. A detailed history from the pa-
rents is needed that is especially focused on the following: 
ambiguity, hirsutism, precocious puberty, amenorrhea, 
infertility, unexplained sudden infant death, or consan-
guinity. Additionally, maternal exposure to hormones in-
cluding exogenous hormones used in assisted reproductive 
techniques and the maternal use of oral contraceptives 
during pregnancy must be assessed [16-21]. Prenatal an-
drogen exposure is clearly associated with psychosexual 
development [16,17]. 
2. Physical examination
History taking should be combined with a general physical 
examination with special attention to the genital anatomy 
[4,12]. Any abnormal virilized or cushingoid appearance of 
the mother should be checked. It is important to examine 
the groin and scrotal or labial folds to determine the pres-
ence of palpable gonads. For differential diagnosis and 
treatment purposes, the presence of one or two gonads is 
an important finding. A palpable gonad is highly sugges-
tive of a testis or rarely an ovotestis (Fig. 1), because the 
ovaries and streak gonad do not descend. An abnormal 
phallic size should be noted by width and stretched length 
measurements. Historically considered, phallus size was 
considered first in the 1960s when any child with a stretch-
ed penile length ＜2.5 cm was likely to be assigned as female 
regardless of the underlying diagnosis [22]. Through a rec-
tal exam, we can confirm the presence of a uterus and 
cervix. Physical examination should be done in a warm 
room and the patient should be placed supine in the frog 
leg position. It is important to note the size, location, and 
texture of both gonads, if palpable. The undescended testis 
could be located in the inguinalcanal, the superficial in-
guinal pouch, at the upper scrotum, or rarely in the femoral, 
perineal, or contralateral scrotal regions. All examinations 
should be done in the presence of the parents, who should 
be informed exactly what will be done and why. Medical 
photography requires sensitivity and consent [23]. 
3. Criteria of physical findings for DSD evaluation
Criteria of physical findings suggestive of DSD include: 1) 
overt genital ambiguity (e.g., cloacal extrophy); 2) appa-
rent female genitalia with an enlarged clitoris and posteri-
or labial fusion (e.g., CAH); 3) apparent male genitalia with 
bilateral undescended testes, hypospadias, or micropenis; 
and 4) discordance between genital appearance and a pre-Korean J Urol 2012;53:1-8
4 Kim and Kim
natal karyotype [4]. Most DSDs are diagnosed in the neo-
natal period. Later presentations in older children often in-
clude: 1) previously unrecognized genital ambiguity, 2) in-
guinal hernia in a girl (e.g., complete androgen insensi-
tivity), 3) delayed or incomplete puberty, 4) primary ame-
norrhea or virilization in a girl, 5) breast development in 
a boy, and 6) gross or cyclic hematuria in a boy [4]. Given 
the spectrum of findings and diagnoses, no specific single 
protocol could be used in the evaluation of DSD patients. 
4. Laboratory tests
The first-line testing in newborns includes karyotyping 
with X- and Y-specific probe detection to determine the 
chromosomal sex; imaging (abdominopelvic ultrasound 
and retrograde genitogram); serum measurements of 
17-hydroxyprogesterone, testosterone, gonadotropins, an-
ti-müllerian hormone, and serum electrolytes to rule out 
salt-wasting CAH; and urinalysis [4,12]. Now many coun-
tries screen newborns for CAH by use of filter-paper blood 
spot 17-hydroxyprogesterone measurements [24]. The tes-
tosterone level can help to determine whether the DSD is 
due to a lack of androgen or cortisone synthesis or rather 
due to a receptor defect. Once the karyotype is determined, 
serum measurements will assist in narrowing the differ-
ential diagnosis. For example, if the 17-hydroxyprogester-
one level is elevated, a diagnosis of CAH can be made. 
Determining the levels of 11-deoxycortisol and deoxy-
corticosterone will help to make a differential diagnosis be-
tween 21-hydroxylase and 11β-hydroxylase deficiencies. If 
the levels are elevated, a diagnosis of 11β-hydroxylase defi-
ciency could be made, whereas low levels confirm 21-hyd-
roxylase deficiency. 
5. Imaging test
Noninvasive and inexpensive ultrasound could be the first 
radiologic examination performed. Abdominopelvic ultra-
soundis used for the evaluation of female internal organs 
and to rule out possible adrenal anomalies. Although it has 
limited accuracy in detecting intra-abdominal testes, ul-
trasound can detect gonads in the inguinal region and can 
identify müllerian anatomy. Retrograde genitogram is 
performed for the anatomical outlining of the urogenital si-
nus and for localizing the position and entry of the urethra 
and vagina into the sinus. 
6. Hormonal stimulation test
In certain circumstances, additional testing such as hu-
man chorionic gonadotropin and adrenocorticotropin stim-
ulation tests to assess testicular and adrenal functions, re-
spectively, are needed. Despite considerable progress in 
the genetic basis of human sexual development, a specific 
molecular diagnosis is identified in only 20% of cases of 
DSDs [25]. Markedly virilized 46,XX DSDs have CAH; 50% 
of undervirilized 46,XY DSDs receive a definitive diagnosis 
[26,27]. Although some gene analyses could be performed 
in clinical service laboratories, gene testing is not routinely 
performed in children with DSDs for reasons of cost, in-
surance, and quality controls [28]. 
7. Diagnostic laparotomy or laparoscopy
In rare cases in which a definite diagnosis cannot be de-
termined and in infants with intra-abdominal or non-
palpable testes in whom DSDs are considered, open or lapa-
roscopic exploration with biopsy of the gonads could be-
come necessary [29]. In some cases, the differential diag-
nosis of DSD depends on the interpretation of the histologic 
features of the gonads [30,31]. Infants with intra-abdomi-
nal or nonpalpable testes in whom the precise diagnosis is 
unavailable with karyotyping and serum study will re-
quire an open or laparoscopic exploration with bilateral 
deep longitudinal gonadal biopsies for histologic evalua-
tion, which will determine the presence of ovotestes, streak 
gonads, or dysgenetic testes, thereby confirming the 
diagnosis. 
GENDER ASSIGNMENT
1. Influencing factors
Initial gender uncertainty is distressful news for families. 
Thereby, gender assignment in a newborn with ambiguous 
genitalia is regarded as a medical emergency, and surgical 
intervention to match the gender as soon as possible after-
medical stabilization is recommended. Influencing factors 
to consider when discussing gender assignment include di-
agnosis, genital appearance, fertility potential, therapeu-
tic/surgical options, and familial views or circumstances 
relating to cultural biases [4,32]. 
2. Gender assignment according to specific diagnosis
When a specific diagnosis can be made, recommendations 
for gender assignment can be based upon outcome data. 
The Chicago Consensus statement did not include specific 
gender assignment recommendations for all diagnoses, 
but some consensus participants have provided more spe-
cific recommendations. For 46,XX CAH, 90% of individuals 
raised as females maintain an assigned female gender 
identity and do not feel gender dysphoric [33]. Therefore, 
there is agreement among healthcare professionals to raise 
these patients as females [12,34]. All patients with 46,XY 
complete androgen insensitivity syndrome (CAIS), who 
are assigned female sex in infancy identify as females and 
there is agreement to raise these patients as females 
[32,35]. More than 60% of 5α-reductase-deficient patients 
assigned female gender in infancy and virilizing at puberty 
and all assigned males live as males and also half of 17β-hy-
droxysteroid dehydrogenase-3 deficiency assigned fema-
les in infancy ultimately change their gender role [36]. 
Therefore, it is recommended to discuss with the families 
when deciding on gender assignment for patients with 
5α-reductase deficiency and 17β-hydroxysteroid dehydro-
genase-3 deficiency diagnosed in infancy. For patients with 
partial androgen insensitivity syndrome, androgen bio-
synthetic defects, and incomplete gonadal dysgenesis, 
there is dissatisfaction with assigned genders in 25% of in-Korean J Urol 2012;53:1-8
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dividuals whether raised as a boy or a girl [37]. The decision 
of sex of rearing in patients with ovotesticular DSDs must 
take into account the potential for fertility based on the de-
gree of gonadal differentiation and genital development. 
Factors to consider for mixed gonadal dysgenesis also in-
clude prenatal androgen exposure, testicular function, 
phallic development, and gonadal location [4]. The general 
recommendations are to raise infants with 46,XX CAH or 
46,XY CAIS as females, whereas for infants diagnosed with 
5α-reductase deficiency or 17β-hydroxysteroid dehydroge-
nase-3 deficiency, a male assignment should be considered 
[38]. 
SURGICAL MANAGEMENT OF AMBIGUOUS 
GENITALIA
1. The aim of surgery
Surgery can relieve parental distress and improve attach-
ment between the child with DSD and the family [39-42]. 
The aim of surgery is to make ambiguous external genitalia 
compatible with assigned gender, preventing urinary ob-
struction or infections, preserving sexual and reproductive 
potentials, and maximizing anatomy to enhance sexual 
function [12]. Surgical corrections usually concern the go-
nads and the outer genitalia and often the presence of a ur-
ogenital sinus. There is no evidence that prophylactic re-
moval of asymptomatic discordant structures is required. 
In general, it is recommended that the decision about geni-
tal surgery should be made by the parents and, when possi-
ble, the patient, under the counseling of the medical team. 
It is important to inform the parents that a functional out-
come is more important than a cosmetic outcome. Patients 
and parents should not be given unrealistic expectations 
about penile reconstruction. 
2. The timing of surgery
In the opinion of some experts, genital surgery in infancy 
that makes an appearance consistent with the gender of 
rearing is of significant psychological support to the family. 
However, others suggest that appearance-altering oper-
ation is not urgent and that it is more appropriate to delay 
surgery until a patient is old enough to be informed fully 
and to provide consent. Although there are still contro-
versies about the optimal timing of the surgery, the 
American Academy of Pediatrics guidelines on the timing 
of genital surgery recommend genitoplasty between 2 and 
6 months of age [43] and many pediatric urologists also rec-
ommend early feminizing genitoplasty [12,44]. Also, some 
studies have demonstrated satisfactory outcomes from 
early surgery [12,37,44,45]. The rationale for early re-
construction is based on the aforementioned guidelines on 
the timing of genital surgery from the American Academy 
of Pediatrics, the beneficial effects of estrogen in early time, 
preventing potentially harmful effects from the communi-
cation between the urinary tract and peritoneum through 
the fallopian tubes, minimizing family concerns, and alle-
viating the risks of stigmatization and gender-identity con-
fusion [39,43,44]. 
3. Surgical procedures
Feminizing genitoplasty for the infants who are to be raised 
as females includes 1) removing the corporal bodies, 2) cre-
ating a normal-looking introitus and labia minora and ma-
jora, and 3) vaginoplasty to provide an adequate opening. 
Masculine reconstruction may include 1) orchiopexy, 2) hy-
pospadias repair, and 3) removal of retained müllerian 
duct structures. 
4. Clitoroplasty
Clitoroplasty should be considered only in cases of severe 
virilization and should be performed combined with repair 
of the common urogenital sinus. Until the 1960s, the princi-
pal surgical procedure for clitoromegaly was clitoridec-
tomy. Amputation of the clitoris leaves a female-appearing 
perineum but orgasmic function and erectile sensation 
may be disturbed. Total removal of the clitoris is contra-
indicated, and when clitoral reduction is performed, spar-
ing the neurovascular bundle is important for the preserva-
tions of intact orgasmic function and erectile sensation 
[46,47]. 
5. Vaginoplasty
Some prefer to correct the external genitalia in a sin-
gle-stage procedure in the newborn period to take advant-
age of all native genital tissue and to avoid scarring 
[40,48,49]. Others advocate postponement with the vagi-
nal reconstruction until puberty when vaginal dilatations 
are more feasible to prevent vaginal stenosis [50]. Because 
the risk of vaginal stenosis is high following vaginoplasty 
before puberty, delayed vaginoplasty could be considered 
if the urinary drainage is adequate. Several options such 
as self-dilatation, skin substitution, and bowel vaginopla-
sty have specific advantages and disadvantages; thereby, 
no one technique could be invariably applied. To prevent 
stenosis, vaginal dilatation can begin 2 weeks after the 
operation. However, vaginal dilatation in early childhood 
is prohibited. 
6. Labioplasty
Labioplasty is performed at the time of the vaginoplasty 
and gives the external genitalia a normal female appear-
ance [51,52]. During clitoroplasty, the remnant skin from 
the clitoris shaft could be used to make the labia minora 
and majora [53]. 
7. Phalloplasty
Currently, there is no tissue available to increase the size 
of an underdeveloped phallus in humans. In patients with 
DSD associated with hypospadias requiring phalloplasty, 
the complexity of this procedure must be discussed during 
the initial counseling and standard surgical repair includ-
ing chordee correction, urethral reconstruction, and judi-
cious testosterone supplementation is recommended [54]. Korean J Urol 2012;53:1-8
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8. Gonadectomy
Although there is controversy regarding the timing of go-
nadectomy, it is commonly recommended soon after diag-
nosis because estrogen-replacement therapy could be 
started [4,55]. The advantages of late gonadectomy include 
breast development and avoidance of poor adolescent com-
pliance with estrogen-replacement therapy. Germ cell ma-
lignancy only occurs in patients with DSD who have 
Y-chromosomal material (GBY region). Testes in patients 
with 46,XY gonadal dysgenesis who are raised as a female 
should be removed to prevent testicular malignancy [55]. 
In patients with androgen biosynthetic defects raised fe-
male, gonadectomy should be performed before puberty. A 
scrotal testis in patients with gonadal dysgenesis is at risk 
for malignancy. Thereby, current recommendations are to 
perform testicular biopsy at puberty, seeking carcinoma in 
situ or undifferentiated intratubular germ cell neoplasia, 
which are premalignant lesions [56]. If positive, the option 
is sperm banking before treatment with local low-dose ra-
diotherapy [56]. In female patients with ovotesticular 
DSD, the tumor risk is low (＜5%), but removal of the tes-
ticular component in early life is recommended to preserve 
fertility potential [57]. 
STEROID REPLACEMENT
Hypogonadism is common in patients with dysgenetic go-
nads, defects in sex-steroid biosynthesis, and resistance to 
androgens. Hormone-replacement therapy is often re-
quired to induce and sustain puberty, induce secondary 
sexual characteristics and pubertal growth spurt, optimize 
bone mineral accumulation, and for psychosocial matura-
tion in patients with DSD [58]. Boys with hypogonadism 
require intramuscular injections of either testosterone cy-
pionate or ethanate for pubertal induction [59]. Other tes-
tosterone preparations such as gels and patches are avail-
able [60-62]. In girls with hypogonadism, estrogen supple-
mentation to induce secondary sexual changes and men-
struations is required. Estrogen can be given orally, by in-
jection, orpatch [59]. A progestin is usually added after 
breakthrough bleeding develops or within 1 to 2 years of 
continuous estrogen. 
PSYCHOSOCIAL SUPPORT
Current recommendations emphasize sensitive, suppor-
tive interactions with families, and full disclosures of the 
risks, benefits, and potential outcomes of intervention to 
allow them to participate as fully as possible in decision 
making and in the continuing care of their child. 
Psychosocial care should be an integral part of manage-
ment to promote positive adaptation. Families and in-
dividuals require ongoing counseling by experienced per-
sonnel to identify maladaptive coping strategies, deal with 
challenges such as gender dysphoria and sexual dysfunc-
tion as they arise, and facilitate age-appropriate in-
formation sharing with their affected child. Other im-
portant resources include access to confidential sexual 
counseling and support groups. Regular follow-up from in-
fancy to adulthood of sexual, psychological, and social pa-
rameters is needed to provide a favorable long-term out-
come for patients with DSD. 
CONCLUSIONS
DSD with ambiguous genitalia is a rare disorder requiring 
prompt investigation and early gender assignment that is 
logically based on a sound knowledge of normal sex deter-
mination and differentiation. Despite the significant ad-
vances that have been achieved, much remains to be clari-
fied in terms of the accurate evaluation and optimal man-
agement of patients with DSD. The complexity of the prob-
lem requires a multidisciplinary team working together, 
including a pediatric urologist, pediatric endocrinologist, 
psychiatrist, and social workers for the proper manage-
ment of patients with DSD. Affected patients and the pa-
rents should be provided with full information to make an 
appropriate choice for gender assignment. The aims of 
management in a newborn with DSD should be the provi-
sion of a stable gender identity with psychological support 
to the family, potential sexual function and fertility, and 
affirmative body image. The surgical correction technique 
and the timing of the operation need to be individualized 
according to medical conditions, experience of the surgeon, 
and the complexity of each case. The general trend is to-
wards early reconstruction with subsequent early and 
long-term management of the patient. The discussion of 
the evaluation and management of patients with DSD 
continues. Future study with further data is essential to 
suggest enhanced clinical guidelines and recommenda-
tions fitting the case of each individual patient. 
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